Pfizer Inc said on Monday it has started a large study testing its new oral antiviral drug to prevent COVID-19 infections, the company said on its website.
The mid-to-late-stage study will test Pfizer’s drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.
“Tackling the COVID-19 pandemic requires both preventions via vaccine and targeted treatment for those who contract the virus,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer on Pfizer’s website.
“We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care, the two have the potential to create an end to the treatment paradigm that complements vaccination in cases where the disease still occurs,” he added.
Pfizer has also started another study in non-hospitalized, symptomatic adult patients.
Pfizer is recognized internationally, and according to the World Health Organization (WHO), Pfizer BioNTech’s vaccine is proven 95% effective against symptomatic SARS-CoV-2 infection.
Albert Borla, Pfizer CEO, said on Sunday that normal life will be back again within a year, but it is likely necessary to receive an annual shot of vaccines against the COVID-19 pandemic.
“The company is able to cover doses production as well as distributing them simultaneously, pointing out that the company, from the beginning of the year until the end of September, have produced two billion doses of the Pfizer vaccine, and will produce another billion doses by the end of 2021, recording a total of three billion doses within one year,” he added.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.